Clinical Pearls on Treating Patients with NRG1 Fusions
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, offer key takeaways and conclude their discussion by offering advice for clinicians treating patients with NRG1 fusion–positive malignancies.
EP: 1.Overview of NRG1 Fusions
EP: 2.NRG1 Fusion Testing Practices
EP: 3.Recent Data on Zenocutuzumab at ESMO 2023
EP: 4.Practical Considerations for Zenocutuzumab in NRG1 Fusion–Positive Malignancies
EP: 5.Clinical Pearls on Treating Patients with NRG1 Fusions
EP: 6.NRG1 Fusions in Lung and GI Cancers
EP: 7.Testing for NRG1 Fusions
EP: 8.Clinical Diagnosis of NRG1 Fusions in NSCLC
EP: 9.Ongoing Research of NRG1-Targeted Therapies
EP: 10.NRG1 Fusions in Pancreatic Cancer and Potential Role of Zenocutuzumab
EP: 11.Key Takeaways for the Treatment of NRG1 Fusion–Positive Malignancies
EP: 12.Defining a Space for NRG1 Fusion–Positive Tumors in Lung and GI Cancers
EP: 13.Inpatient vs Outpatient Use of Teclistamab in Multiple Myeloma
Educational support for this activity provided by Merus.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
